<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139585">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01952782</url>
  </required_header>
  <id_info>
    <org_study_id>2013P001543</org_study_id>
    <nct_id>NCT01952782</nct_id>
  </id_info>
  <brief_title>Neuropeptides in Human Reproduction</brief_title>
  <official_title>Neuropeptides in Human Reproduction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are seeking healthy volunteers and volunteers with reproductive disorders
      for the study of the role of dynorphin in the reproductive system. Dynorphin is a naturally
      occurring opioid hormone that is blocked by naloxone.

      We hypothesize that naloxone, by blocking dynorphin, will stimulate production of GnRH and
      kisspeptin, 2 other naturally occurring reproductive hormones.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Luteinizing Hormone (LH) level</measure>
    <time_frame>6 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Follicle Stimulating Hormone (FSH) level</measure>
    <time_frame>6 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Testosterone (Males)</measure>
    <time_frame>6 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estradiol (Females)</measure>
    <time_frame>6 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Blood Count (CBC)</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Urea Nitrogen (BUN)</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Function Studies</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Hypogonadotropic Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Naloxone, Kisspeptin, GnRH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study will involve 3 visits:
Outpatient screening visit
Inpatient admission where subjects receive an intravenous infusion of naloxone, intravenous doses of kisspeptin 112-121, and intravenous doses of Gonadotropin Releasing Hormone (GnRH)
Outpatient follow-up visit</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kisspeptin 112-121</intervention_name>
    <description>Subjects will receive up to 10 intravenous doses of kisspeptin 112-121</description>
    <arm_group_label>Naloxone, Kisspeptin, GnRH</arm_group_label>
    <other_name>Metastin 45-54</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxone</intervention_name>
    <description>Subjects will receive one intravenous dose of naloxone followed by an intravenous infusion of naloxone.</description>
    <arm_group_label>Naloxone, Kisspeptin, GnRH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonadotropin Releasing Hormone (GnRH)</intervention_name>
    <description>Subjects will receive up to 10 doses of intravenous Gonadotropin Releasing Hormone (GnRH)</description>
    <arm_group_label>Naloxone, Kisspeptin, GnRH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 21-40 (healthy men and regularly cycling women) OR ages 18-75 (men and women
             with hypogonadotropic hypogonadism (HH))

          -  Normal blood pressure (systolic BP &lt;140 mm Hg, diastolic BP &lt;90 mm Hg)

          -  White blood cell, plates, prolactin, and thyroid stimulating hormone (TSH)within
             90%-110% of laboratory reference range

          -  Negative urine drug screen panel

          -  Hemoglobin:

               1. For healthy men and healthy regularly cycling women: normal

               2. For men and women with HH: No less than 0.5 gm/dL below the lower limit of the
                  reference range for normal women

          -  Blood urea nitrogen (BUN), creatinine, liver function tests not elevated

          -  For healthy subjects: Normal reproductive function and history

          -  For healthy subjects: Body Mass Index (BMI) 18.5-30kg/m2

          -  For subjects with HH: All medical conditions stable and well controlled

        Exclusion Criteria:

          -  History of medication reaction requiring emergency medical attention

          -  Illicit drug use

          -  Consumption of more than 10 alcoholic drinks per week

          -  Difficulty with blood draws

          -  Currently seeking fertility, breastfeeding, or pregnant

          -  For healthy subjects: history of chronic disease and prescription medication use
             (with the exception of seasonal allergy medication)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephanie B Seminara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cindy Li, BA</last_name>
    <phone>617-724-1083</phone>
    <email>cli17@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cindy Li, BA</last_name>
      <phone>617-724-1083</phone>
      <email>cli17@partners.org</email>
    </contact>
    <investigator>
      <last_name>Stephanie B Seminara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yee-Ming Chan, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maragret Lippincott, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 13, 2013</lastchanged_date>
  <firstreceived_date>September 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Stephanie B. Seminara, MD</investigator_full_name>
    <investigator_title>Associate in Medicine</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
